March 17 (Reuters) - Gyre Therapeutics Inc GYRE.O:
GYRE THERAPEUTICS ANNOUNCES CHINA’S NMPA GRANTS PRIORITY REVIEW TO THE NDA FOR HYDRONIDONE (F351) FOR CHB-INDUCED LIVER FIBROSIS TREATMENT
GYRE THERAPEUTICS INC - CO THROUGH UNIT PANS FORMAL NDA SUBMISSION FOR HYDRONIDONE IN NEAR FUTURE